Browsing by Author "Sriuranpong, V."
Now showing 1 - 6 of 6
- Results Per Page
- Sort Options
Item Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%(2019) Sezer, A.; Gogishvili, M.; Bentsion, D.; Kilickap, S.; Lowczak, A.; Gumus, M.; Gladkow, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Lee, S.; Li, S.; Snodgrass, P.; Navarro, M.; Lowy, I.; Rietschel, P.Item Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC(2021) Kilickap, S.; Sezer, A.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Makharadze, T.; Paydas, S.; Nechaeva, M.; Seebach, F.; Weinreich, D.M.; Yancopoulos, G.D.; Gullo, G.; Lowy, I.; Rietschel, P.Item EMPOWER-Lung 1: A Randomized, Open-Label, Multi-National, Phase III Trial of Cemiplimab, A Human PD-1 Monoclonal Antibody, Versus Chemotherapy In First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With PD-L1 >= 50%(2018) Sriuranpong, V.; Altundag, O.; Clingan, P.; Rizvi, N.; Frontera, O. Aren; Sezer, A.; Paydas, S.; Shavdia, M.; Bondarenko, I.; Gladkov, O.; 0000-0003-0197-6622; 0000-0003-4642-3693; W-9219-2019; F-3132-2018Item EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%(2020) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvilli, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Gullo, G.; Lowy, I.; Rietschel, P.; 0000-0002-6445-1439; AAD-2667-2020Item EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%(2020) Sezer, A.; Kilickap, S.; Gumus, M.; Bondarenko, I.; Ozguroglu, M.; Gogishvili, M.; Turk, H. M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Li, S.; Lee, S.; Gullo, G.; Lowy, I.; Rietschel, P.; 0000-0002-6445-1439; AAD-2667-2020Item Phase I/II Study of Spartalizumab (PDR001), An Anti-PD1 Mab, in Patients with Advanced Melanoma or Non-Small Cell Lung Cancer(2018) Lin, C-C.; Taylor, M.; Boni, V.; Brunsvig, P. F.; Geater, S. L.; Salvagni, S.; Garrido Lopez, P.; Ozguroglu, M.; Sriuranpong, V.; Ponce Aix, S.; Ascierto, P. A.; Fasolo, A.; Sezer, A.; Kowalski, D. M.; Faris, J. E.; Cameron, S.; Mataraza, J.; Wu, H.; Antona, V.; Ochoa de Olza, M.